Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Rating of “Moderate Buy” from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.08.

HIMS has been the topic of several recent research reports. Truist Financial boosted their price target on Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Citigroup boosted their price target on Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Guggenheim upped their target price on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 97,208 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at approximately $494,835.74. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Oluyemi Okupe sold 9,912 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $15.82, for a total value of $156,807.84. Following the completion of the transaction, the chief financial officer now owns 168,627 shares of the company’s stock, valued at $2,667,679.14. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The disclosure for this sale can be found here. Insiders sold a total of 723,602 shares of company stock worth $9,607,432 in the last three months. 31.63% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HIMS. FNY Investment Advisers LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth $48,000. Belpointe Asset Management LLC bought a new position in shares of Hims & Hers Health in the third quarter worth $76,000. EMC Capital Management boosted its stake in Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after buying an additional 5,332 shares in the last quarter. Certuity LLC bought a new position in Hims & Hers Health during the fourth quarter valued at about $109,000. Finally, Corton Capital Inc. bought a new position in Hims & Hers Health during the third quarter valued at about $122,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $12.92 on Friday. The stock has a 50-day simple moving average of $13.99 and a 200-day simple moving average of $10.41. The stock has a market capitalization of $2.77 billion, a P/E ratio of -117.36 and a beta of 0.97. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.05) EPS. Analysts predict that Hims & Hers Health will post 0.11 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.